Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Treatment of hypokalemia,Prevention of hypokalemia,Replacement of potassium losses,Provision of fluid and caloric needs when potassium supplementation is required
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
Intravenous; typical adult dose is 10-20 m Eq/hour, not exceeding 40 m Eq/hour or 150 m Eq/day, with continuous cardiac monitoring and serum potassium monitoring.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 m Eq per 100 m L (approximately 20 m Eq/L).
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
Negligible (<5%). Potassium is not significantly bound to plasma proteins; it exists as free ion in serum.
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
Approximately 0.5-0.6 L/kg (total body water); reflects distribution throughout extracellular and intracellular spaces. Potassium is predominantly intracellular (98% of total body potassium is in cells); Vd for administered potassium is large due to cellular uptake.
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Intravenous: 100% (complete bioavailability). Oral: about 90% absorbed; however, this formulation is for IV administration only.
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce total daily dose by 25-50%; GFR < 10 m L/min: reduce dose by 50-75% and monitor potassium closely. Avoid if anuria.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
No specific adjustment based on Child-Pugh score; however, monitor potassium levels and renal function closely due to potential hepatorenal syndrome.
No adjustment required for hepatic impairment.
Intravenous; 0.2-0.5 m Eq/kg/hour, not exceeding 1 m Eq/kg/hour or 40 m Eq/m²/hour; adjust based on serum potassium and clinical status.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
Cautious dosing: initial dose at lower end of adult range (10 m Eq/hour) with close monitoring of renal function and serum potassium due to decreased renal reserve and higher risk of hyperkalemia.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
Potassium chloride injection concentrate must be diluted before use to avoid fatal hyperkalemia.
No FDA black box warning.
Hyperkalemia risk; monitor serum potassium levels,Cardiotoxicity; ECG monitoring recommended,Risk of extravasation; do not administer intramuscularly,Use with caution in renal impairment, adrenal insufficiency, or conditions predisposing to hyperkalemia,Do not administer if solution is discolored or contains particulate matter
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Hyperkalemia,Severe renal failure with oliguria or anuria,Adrenal insufficiency,Concomitant use of potassium-sparing diuretics,Crush syndrome,Severe hemolytic reactions
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, salt substitutes) while receiving this IV solution to prevent hyperkalemia.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infusion may cause maternal electrolyte imbalance potentially affecting fetus.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Potassium and dextrose are normal constituents of breast milk. No adverse effects anticipated. Use considered safe during breastfeeding. M/P ratio not established.
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No dose adjustment required. Use standard adult dosing, adjusted for maternal weight and clinical status. Monitor for fluid overload and electrolyte disturbances.
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
This solution provides 22 m Eq/L of potassium chloride and 5% dextrose. Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia. Monitor serum potassium levels closely; rate of infusion should not exceed 10 m Eq/hour typically. Avoid in patients with oliguria or anuria. Do not administer undiluted; container is for intravenous use only.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
This medication is given through a vein to provide potassium and sugar.,Tell your healthcare provider if you have kidney problems, heart disease, or are taking any other medications.,Report any symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensations.,You may experience pain or irritation at the IV site; inform your nurse if this occurs.,Do not stop or change the infusion rate on your own.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCONATE, answered by our medical review team.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCONATE depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous; typical adult dose is 10-20 m Eq/hour, not exceeding 40 m Eq/hour or 150 m Eq/day, with continuous cardiac monitoring and serum potassium monitoring.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not known to be teratogenic. No fetal risks have been identified in any trimester. Dextrose is a physiological nutrient. Overdose or rapid infus. CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.